Analysts See SELLAS Life Sciences Group Inc. (SLS) Rising 88.57%

Publicly-traded company SELLAS Life Sciences Group Inc. (NASDAQ:SLS) had a closing price of $0.20 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $1.75, this means that the stock is underpriced by 88.57%. In the past 52 weeks the company’s stock price has moved within the range of $0.10 to $2.46.

This particular stock’s 5-day moving average is 0.15, its 20-day moving average is 0.13 and its 100-day moving average is 0.14. SELLAS Life Sciences Group Inc. (SLS) currently has 209.56M shares outstanding, which means that its market capitalization is $42.96M.

The Details: SELLAS Life Sciences Group Inc. (SLS) Financial Health

Return on Assets, which is expressed as a percentage, tells us how well a public company is using its assets to turn a profit. The larger the percentage, the better it is At the moment, SELLAS Life Sciences Group Inc. Return on Assets is -133.50%.

What Does Wall Street Say about Company?

When selecting potential stocks to buy, many investors want to find out what Wall Street professionals are thinking about the company beforehand – like what the average analyst rating is. At the moment, the average analyst rating for SLS is Buy. Out of 1 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 0 rated it hold, and 1 rated it a Buy.

Understanding Profitability at SELLAS Life Sciences Group Inc. (SLS)

Wall Street analysts, on average, are forecasting the company’s EPS to be -0.02, compared to -0.55 reported in the same quarter last year.